Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone forming agent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neuromuscular diseases, and metabolic disorders. Acceleron Pharma, Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Current Team (11)Update
Funding Rounds (6) - $113.7MUpdate
Board Members and Advisors (13)Update
Celgene discovers, develops and commercializes innovative therapies to treat cancer and...
Advanced Technology Ventures focuses on investing in the ICT, infrastructure, consumer...
OrbiMed is a healthcare-dedicated investment firm, with approximately $5 billion in assets under...
Venrock is a venture capital firm investing in technology and healthcare companies.
Polaris Partners is a venture company investing in digital media, life sciences, and enterprise...
Realizing entrepreneurial innovation is the mission of Flagship Ventures. The firm operates...
Sutter Hill Ventures has financed technology-based start-ups and assisted entrepreneurs in...
128 Sidney Street
Cambridge, MA 02139
- 09/19/13 -nasdaq.com